Genedata Provides Expressionist Platform to U.S. Food and Drug Administration
News Nov 29, 2007
Genedata has announced an agreement with the National Center for Toxicological Research of the U.S. Food and Drug Administration for the company’s Genedata Expressionist® biomarker discovery platform.
Genedata Expressionist is a modular computational platform for biomarker discovery that integrates transcriptomics, proteomics and metabolomics data within a single enterprise software system.
With sophisticated high-throughput data processing and automated workflows for quality assessment, statistical analysis and interpretation functionalities, the platform provides a single-point-of-access for all experimental data, including sample information, raw and pre-processed data, analysis results and documentation with reports.
Weida Tong, Director of the Center for Toxicoinformatics at the U.S. Food and Drug Administration (FDA), said, “Given the vast quantities and varied sources of microarray data for the voluntary genomics data submission (VGDS) program, it is vital that my team have the most effective set of tools available to assay the data quality of submitted results.
The automated quality assurance tools available in Expressionist will enable us to ensure reproducible and reliable results and to provide quantitative feedback where data quality is in question.”
Dr. Jens Hoefkens, Managing Director of Genedata, said, “We are delighted that the FDA has chosen Expressionist to ensure that reviewers of our customers` data at the FDA can use the same suite of tools and applications to identify markers based on rigorous quality control standards.”
Genome-wide association studies (GWAS) look at large populations to find genes that contribute to common, multi-gene traits like height or obesity. These comprehensive studies frequently turn up large numbers of tiny genetic variations that occur more often in people who are tall, obese, etc. So which genes should scientists investigate further?READ MORE
In recent years, numerous studies have shown that people who don't get enough sleep are at greater risk of stroke and heart attack. A study found that people who sleep fewer than 7 hours per night have lower blood levels of three physiological regulators, or microRNAs, which influence gene expression and play a key role in maintaining vascular health.